Other substances

Flumatinib

A protein tyrosine kinase inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Flumatinib is a tyrosine kinase inhibitor investigated for its antineoplastic activity. It inhibits Bcr-Abl, platelet-derived growth factor receptor, and mast/stem cell growth factor receptor kinases. The inhibition has a potential to block downstream signalling with a possible application in chronic myeloid leukaemia, acute lymphoblastic leukaemia, and acute myelogenous leukaemia treatment (NCIt).

Flumatinib on DrugBank
Flumatinib on PubChem

 

Structure image - Flumatinib

CC1=C(C=C(C=N1)NC(=O)C2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5

Supporting references

Link Tested on Impact factor Notes Publication date
Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing
Small molecule In vitro 		in vitro bacteria-based assay 3.82

Displayed inhibitory activity against the potential ion channel ORF3a of SARS-CoV-2 in a bacterial model assay.

 Mar/23/2021
Export (.csv)